1. Preoperative Anemia Management: What’s New in 2020?
- Author
-
Andy Ngo, Christine Cahill, Daniel A. Rubinger, Marjorie Gloff, and Majed A. Refaai
- Subjects
medicine.medical_specialty ,education.field_of_study ,medicine.diagnostic_test ,Anemia ,business.industry ,Transferrin saturation ,Population ,030208 emergency & critical care medicine ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Anesthesiology and Pain Medicine ,030202 anesthesiology ,hemic and lymphatic diseases ,Anesthesiology ,medicine ,Preoperative anemia ,Hemoglobin ,Intensive care medicine ,business ,education ,Serum ferritin ,Mean corpuscular volume - Abstract
The purpose of this article is to review the relevant evidence regarding the clinical impact of preoperative anemia, current methods of identifying anemia in the surgical population, and the current and upcoming evidence for the treatment modalities targeting preoperative anemia. Preoperative anemia continues to be identified as a contributor to poor outcomes in the surgical population. Identifying anemia typically starts with hemoglobin and mean corpuscular volume. Recent laboratories have also started using iron studies with serum ferritin and transferrin saturation. Oral and IV iron have demonstrated efficacy in treating preoperative anemia in terms of increasing hemoglobin preoperatively and reducing allogeneic blood transfusions. However, few studies have demonstrated an impact on patient outcomes, morbidity, and mortality. Additionally, several meta-analyses have demonstrated the benefit of adding erythropoietin-stimulating agents to improve anemia. Preoperative anemia is very common and is thought to be a contributor to poor outcomes. IV iron is currently recommended by several guidelines as the primary treatment modality for preoperative anemia. Two ongoing studies hope to provide clarity on the effect of IV iron on patient outcomes including morbidity and mortality in cardiac and non-cardiac surgical populations.
- Published
- 2020